Idera Pharma reports clinical safety and efficacy update from ILLUMINATE-204 trial
Idera reported data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®). The combination regimen continues to be generally well tolerated. December 14, 2018